click below
click below
Normal Size Small Size show me how
GCN N170 Diabetes
N170 Diabetes Study Aid
| Question | Answer |
|---|---|
| Hyperglycemia | FBS >110mg/dl |
| Hypoglyemia | Blood Glucose <60mg/dL |
| Risk Factors | BMI >27, HTN >140/90, family history, elevated triglycerides & HDL |
| Impaired Glucose Tolerance | FBS 110-126mg/dL |
| Diabetes Mellitus | FBS >126mg/dL |
| Ketone | By product of Fat breakdown; circulate in both blood and urine |
| Glycated Hemoglobin | HgbA1C; normally 4-6 %, or 4.0-6.0 |
| Rapid Acting Insulins | Aspart =(Novolog) Lispro =(Humolog) |
| Short Acting Insulins | Humolog R; Novolog R; Iletin II R |
| Intermediate Acting Insulins | NPH; Humulin N; Novolin N; Novolin L |
| Long Acting Insulins | Ultralente |
| Very Long Acting Insulins | Glargine (Lantus) |
| Lantus Insulin | Onset = 1 hour. Peakless = used as a basal insulin. Duration = 24 hours |
| Lispro (Humalog) Onset | Onset = 10-15 minutes |
| Lispro (Humalog) Peak | Peak = 1 hour |
| Lispro (Humalog)Duration | Duration = 2-4 hours |
| Aspart (Novolog)Onset | Onset = 5-15 min |
| Aspart (Novolog)Peak | Peak = 40-50 minutes |
| Aspart (Novolog) Duration | Duration = 2-4 hours |
| Humolog R or Novolin R Peak *usually administered 20-30 minutes before meal | Peak = 2-3 hours |
| Humolog R or Novolin R Onset | Onset = 1/2-1 hour |
| Humolog R or Novolin R Duration | Duration = 4-6 hours |
| NPH Onset *Usually administered after food | Onset = 2-4 hours |
| NPH Peak | Peak = 4-12 hours |
| NPH Duration | Duration = 16-20 hours |
| Humulin N or Novolin N ONset | Onset = 3-4 hours |
| Humulin N or Novolin N Peak | Peak = 4-12 hours |
| Humulin N or Novolin N Duration | Duration = 16-20 hours |
| Ultra Lente Onset*used primarily to control Fasting Glucose | Onset = 6-8 hours |
| Ultra Lente Peak | Peak = 12-16 hours |
| Ultra Lente Duration | Duration 20-30 hours |
| Lente Onset | Onset = 3-4 hours |
| Lente Peak | Peak = 4-12 hours |
| Lente Duration | Duration 16-20 hours |
| Sulfonylureas | Chlorpopamide (Diabenese);Tolazamide (Tolinase);Tolbutamide (Orinase);Aceohexamide * "mide" - sulfonylurea |
| Sulfonylureas | Glipizide (Glucatrol);Glyburide (Micronase, Diabeta);Glimepiride (Amaryl) *"ide" = sulfonylureas |
| Biguanides | Metformin (Glucophase, Glucophage) |
| Alpha Glugosidase Inhibitors | Acarbose (Precose); Miglitol (Glyset) |
| Non- Sulfonylurea Insulin Secretagogues | Repalinide (Prandin)= meglitinide |
| Thiaxolidinediones (glitazones) | Pioglitazone Actos); Rosiglitazone (Avandia) |
| SulfonylureaMechanism of Action | Oral Antidiabetic Agent that: Stimulates Beta cells to secrete insulin |
| Biguanides | Oral Antidiabetic Agent that: Inhibits production of glucose by the liverAlso increases body tissue sensitivity to insulin |
| Alpha-Glucosidase Inhibitors | Oral Antidiabetic Agent that: Does not increase insulin secretion. Delays absorption of carbohydrates in the intestine resulting in slow entry of glucose into systemic circulation |
| Non-Sulfonylurea Insulin Secretagogues | Oral Antidiabetic Agent that: Stimulates pancreas to increase insulin |
| Thiazolidinediones | Oral Antidiabetic Agent that: Increases body tissue sensitivity to insulin; stimulate insulin receptor sites to lower blood glucose and improves the action of insulin |
| S&S Hypoglycemia | Adrenergic symptoms-Increased epinephrine and norepinephrine resulting in;sweating, tremor, tachycardia nervousness and hunger |
| S&S Hypoglycemia | CNS Symptoms: headache, inability to concentrate, lightheadedness, confusion, numbness of the lips and tongue, irrational behavior, dowble vision, drowsiness progressing to seizures and loss of consciousness. |
| S&S Hyperglycemia | Symptoms -Polyuria; Polydipsia; Orthostatic hypotension; Acetone Breath "fruity breath" |
| Long Term Complications of Diabetes Mellitus | Coronary Artery Disease, Cerebral Vasular Disease & Peripheral Vascular Disease |
| Long Term Complications of DM | Retinopathy, cataracts, glaucoma |
| Long Term Complications of DM | Nephropathy - renal disease |